Biomarin, a top big biotech company, focusses on developing and commercializing innovative biopharmaceuticals for serious diseases and medical conditions. The company’s partnering activity is reviewed in the article. The following figure shows the level of Biomarin partnering deal announcements since 2009.
Figure 1: Biomarin partnering deals 2009-2014
Source: Current Agreements, 2014
Biomarin’s partnering activity has seen peaks and dips since 2009.The company has a line of pipeline products and this could mean more partnering opportunities in the future.
Analysis of the partnering deals shows a strong emphasis on partnerships in immunology diseases. The company specifically works on immunological diseases like systemic lupus erythematosus.
The following table provides an overview of the partnering deals announced by Biomarin based on therapy area disclosed. Our report provides more detailed insight into the precise therapeutic target of each deal. See: Report: Partnering Agreements with Biomarin 2009-2014
Figure 2: Biomarin partnering deals by therapy area 2009-2014
Source: Current Agreements, 2014
Further analysis of these deals shows that Biomarin has a preference for licensing, collaborative R&D and co development deals, similar to many other top pharmaceutical or big biotech companies. Such partnering deals provide the right for Biomarin to exploit the licensors technology in return for payment of upfront, development and sales, and royalty payments.
The following table provides an overview of the partnering deals announced by Biomarin based on deal type disclosed.
Figure 3: Biomarin partnering deals by deal type 2009-2014
Source: Current Agreements, 2014
When looking at stage of development at partnering deal signing, the most popular stage at signing is phase III with 7 deal announcements. Biomarin actively pursues strategies to enhance its product portfolio. The company has an extensive product pipeline in development stages from preclinical through to phase III stages.
The following table provides an overview of the partnering deals announced by Biomarin based on stage of development at signature.
Figure 4: Biomarin partnering by stage of development 2009-2014
Source: Current Agreements, 2014
Biomarin has signed over 10 partnering, collaborative R&D and licensing deals since 2009 with companies like Pfizer, Myriad Genetics and recently with Repligen for histone deacetylase inhibitors.
The following provides a summary of the top deals by headline value.
Figure 5: Top Biomarin partnering deals by headline value 2009-2014
Source: Current Agreements, 2014
Our report provides more detailed insight into the details of each deal.
See: Partnering Agreements with Biomarin 2009-2014
Biomarin partnering at Current Agreements
View all partnering deals for Biomarin: 2014 | 2013 | 2012 | 2011 | 2010 | 2009
Full details on each deal can be found at CurrentAgreements (subscription required)
More
Summary profile data for Biomarin
Partnering interests for Biomarin
Available reports from Current Partnering
Report: Partnering Agreements with Biomarin 2009-2014
Report: Partnering Deals and Alliances with Big Biotech
Available resources for deal coverage for Biomarin
Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more
Read: more on Biomarin company profile, recent partnering, M&A and financing news and articles
Related
Report: Finding Biopharma Licensing and Collaboration Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now
Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter
